Skip to content

The Role of Muscle Protein Breakdown in the Regulation of Muscle Quality in Frail Elderly Individuals

The Role of Muscle Protein Breakdown in the Regulation of Muscle Quality in Frail Elderly Individuals

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03326648
Enrollment
34
Registered
2017-10-31
Start date
2016-09-01
Completion date
2018-03-01
Last updated
2018-04-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sarcopenia

Keywords

Sarcopenia, Frailty, Strength training, Autophagy

Brief summary

The purpose of this study is to investigate mechanisms underlying the reduction in muscle quality (the ratio between muscle strength and muscle size) with aging, and to investigate how these factors are affected by strength training and protein supplementation. It is already established that muscle quality defined as the ratio between the strength and the size of a muscle is improved with strength training, even in frail elderly individuals. However, the relative contribution of factors such as activation level, fat infiltration, muscle architecture and single fiber function is unknown. The main focus of this study is to investigate the relationship between muscle quality and muscle protein breakdown, as insufficient degradation of proteins is hypothesized to negatively affect muscle quality.

Detailed description

Aging is associated with impaired skeletal muscle function. This is evident not only by a reduced capacity to generate force and power at the whole muscle level, but also by a decline in individual muscle fiber contraction velocity and force generation. Combined with muscle atrophy, these changes lead to reduced muscle strength and quality and loss off physical function with age. Clinically, muscle quality may be a better indicator of overall functional capacity than absolute muscle strength. Thus, identifying the mechanisms underlying the age-related loss of muscle quality is of high relevance for the prevention of functional impairment with aging. The explanation for the loss of muscle quality with aging seems to be multifactorial, with alterations in voluntary muscle activation, muscle architecture, fat infiltration and impaired contractile properties of single muscle fibers being likely contributors. Single fiber specific force seems to be related to myosin heavy chain (MHC) content, which is thought to reflect the number of available cross-bridges. The reduction of single fiber specific force with aging may thus be a consequence of reduced synthesis of MHC and/or increased concentration of non-contractile tissue (e.g. intramyocellular lipids). Some studies in mice also indicate attenuated activity in some of the pathways responsible for degradation of muscle proteins with aging (especially autophagy). As a result, damaged proteins and organelles are not removed as effectively as they should, which could ultimately compromise the muscle's ability to produce force. In addition, reduced efficiency of mitophagy and lipophagy (two specific forms of autophagy), may indirectly affect single fiber specific force, through oxidative damage by reactive oxygen species (ROS) and increased levels of intramyocellular lipids, respectively. Although animal studies indicate attenuated autophagic function, exercise seems to restore the activity in this pathway. Whether this also is the case in humans is unknown. Thus, the purpose of this study is to investigate how the different factors contributing to reduced muscle quality in frail elderly individuals, with emphasis on the relationship between muscle quality and autophagy, may be counteracted by a specific strength training program targeting muscle quality and muscle mass. In this randomized controlled trial the investigators will aim to recruit frail elderly individuals, as muscle quality is shown to be low in this population. As a consequence, the potential for improved muscle quality is expected to be large. Subjects will be randomized to two groups; one group performing strength training twice a week for 10 weeks in addition to receiving daily protein supplementation. The other group will only receive the protein supplement. Several tests will be performed before and after the intervention period, including a test day where a biopsy is obtained both at rest, and 2.5 hours following strength training + protein supplementation or protein supplementation only. This will provide information about the regulation of muscle protein breakdown in a resting state, following protein intake and following strength training in combination with protein intake. As this will be done both before and after the training period, it will also provide information on how long-term strength training affects the activity in these systems.

Interventions

OTHERStrength training

Heavy load strength training performed twice a week for 10 weeks.

DIETARY_SUPPLEMENTProtein supplementation

Dietary protein supplement (protein-enriched milk with 0,2 % fat). 0,33 l each day for 10 weeks.

Sponsors

University of Padova
CollaboratorOTHER
University of Copenhagen
CollaboratorOTHER
Tine
CollaboratorINDUSTRY
Truls Raastad
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE
Masking
SINGLE (Outcomes Assessor)

Masking description

Subjects and testers will not be blinded. All analyses of muscle samples will be performed blinded.

Eligibility

Sex/Gender
ALL
Age
65 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Age \> 65 * Frail or pre-frail according to the Fried Frailty Criteria or Short Physical Performance Battery (SPPB) score \<6. * Mini Mental State Examination score \> 18

Exclusion criteria

* Diseases or injuries contraindicating participation * Lactose intolerance * Allergy to milk * Allergy towards local anesthetics (xylocain) * Use of anticoagulants that cannot be discontinued prior to the muscle biopsy

Design outcomes

Primary

MeasureTime frameDescription
Single fiber specific forceChange from baseline at 10 weeksA measure of muscle quality at the single fiber level. Biopsies obtained from m. Vastus Lateralis

Secondary

MeasureTime frameDescription
Muscle size of m. quadricepsChange from baseline at 10 weeksCross-sectional area of m. quadriceps measured by a Computed Tomography scan
Fat infiltration of m. quadricepsChange from baseline at 10 weeksFat infiltration of m. quadriceps measured by a Computed Tomography scan
Lean massChange from baseline at 10 weeksMeasured by a Dual-energy X-ray absorptiometry (DXA) scan
Fat massChange from baseline at 10 weeksMeasured by a Dual-energy X-ray absorptiometry (DXA) scan
Bone mineral densityChange from baseline at 10 weeksMeasured by a Dual-energy X-ray absorptiometry (DXA) scan
Muscle strength of m. quadricepsChange from baseline at 10 weeksMaximal isometric and dynamic muscle strength of m. quadriceps
Muscle activationChange from baseline at 10 weeksVoluntary activation level during a maximal isometric knee extension using the interpolated twitch technique
Fractional Breakdown RateMeasured over the last 14 days of the intervention periodMeasurement of fractional breakdown rate by the use of orally provided Deuterium Oxide, biopsies and blood samples
m. Vastus Lateralis thicknessChange from baseline at 10 weeksMeasured by ultrasound
Chair stand performanceChange from baseline at 10 weeksTime (sec) to stand up from a chair five times
Habitual gait velocityChange from baseline at 10 weeksTime (sec) to walk 6 meters at habitual gait velocity
Maximal gait velocityChange from baseline at 10 weeksTime (sec) to walk 6 meters as fast as possible
Level/cellular location of Microtubule-associated protein 1A/1B-light chain 3 (LC3)Before and 2.5 hours after acute training session both at baseline and after 10 weeksBiopsies from m. Vastus Lateralis analyzed by western blot
Level/cellular location of p62/Sequestosome-1Before and 2.5 hours after acute training session both at baseline and after 10 weeksBiopsies from m. Vastus Lateralis analyzed by western blot
Level/cellular location of Lysosome-associated membrane glycoprotein 2 (LAMP2)Before and 2.5 hours after acute training session both at baseline and after 10 weeksBiopsies from m. Vastus Lateralis analyzed by western blot
Level/cellular location of forkhead box O3 (FOXO3a)Before and 2.5 hours after acute training session both at baseline and after 10 weeksBiopsies from m. Vastus Lateralis analyzed by western blot
Phosphorylation status and total level of ribosomal protein S6 kinase beta-1(P70S6K)Before and 2.5 hours after acute training session both at baseline and after 10 weeksBiopsies from m. Vastus Lateralis analyzed by western blot
Phosphorylation status and total level of eukaryotic elongation factor 2 (eEF-2)Before and 2.5 hours after acute training session both at baseline and after 10 weeksBiopsies from m. Vastus Lateralis analyzed by western blot
Phosphorylation status and total level of eukaryotic translation initiation factor 4E-binding protein 1 (4EBP-1)Before and 2.5 hours after acute training session both at baseline and after 10 weeksBiopsies from m. Vastus Lateralis analyzed by western blot
Level/cellular location of muscle RING-finger protein-1 (Murf-1)Before and 2.5 hours after acute training session both at baseline and after 10 weeksBiopsies from m. Vastus Lateralis analyzed by western blot
Level/cellular location of ubiquitin (Ub)Before and 2.5 hours after acute training session both at baseline and after 10 weeksBiopsies from m. Vastus Lateralis analyzed by western blot
Blood serum glucoseChange from baseline at 10 weeksFasted
Blood serum insulinChange from baseline at 10 weeksFasted
Blood plasma Hemoglobin A1c (HbA1c)Change from baseline at 10 weeksFasted
Blood serum TriglyceridesChange from baseline at 10 weeksFasted
Blood serum High-density lipoproteins (HDL)Change from baseline at 10 weeksFasted
Blood serum Low-density lipoproteins (LDL)Change from baseline at 10 weeksFasted
Blood serum C-reactive protein (CRP)Change from baseline at 10 weeksFasted
forkhead box protein O3 (FOXO3A) mRNABefore and 2.5 hours after acute training session both at baseline and after 10 weeksBiopsies from m. Vastus Lateralis analyzed by western blot
forkhead box protein O1 (FOXO1) mRNA mRNABefore and 2.5 hours after acute training session both at baseline and after 10 weeksBiopsies from m. Vastus Lateralis analyzed by western blot
hepatocyte growth factor (HGF) mRNABefore and 2.5 hours after acute training session both at baseline and after 10 weeksBiopsies from m. Vastus Lateralis analyzed by western blot
insulin-like growth factor I (IGF1) mRNABefore and 2.5 hours after acute training session both at baseline and after 10 weeksBiopsies from m. Vastus Lateralis analyzed by western blot
myostatin (MSTN) mRNABefore and 2.5 hours after acute training session both at baseline and after 10 weeksBiopsies from m. Vastus Lateralis analyzed by western blot
E3 ubiquitin-protein ligase TRIM63 (TRIM63) mRNABefore and 2.5 hours after acute training session both at baseline and after 10 weeksBiopsies from m. Vastus Lateralis analyzed by western blot
p62/Sequestosome-1 mRNABefore and 2.5 hours after acute training session both at baseline and after 10 weeksBiopsies from m. Vastus Lateralis analyzed by western blot
muscle RING-finger protein-1 (Murf-1) protein 1 (4EBP-1) mRNABefore and 2.5 hours after acute training session both at baseline and after 10 weeksBiopsies from m. Vastus Lateralis analyzed by western blot
Atrogin1 mRNABefore and 2.5 hours after acute training session both at baseline and after 10 weeksBiopsies from m. Vastus Lateralis analyzed by western blot
Microtubule-associated protein 1A/1B-light chain 3 (LC3) mRNABefore and 2.5 hours after acute training session both at baseline and after 10 weeksBiopsies from m. Vastus Lateralis analyzed by western blot
BCL2/adenovirus E1B interacting protein 3 (BNIP3) mRNABefore and 2.5 hours after acute training session both at baseline and after 10 weeksBiopsies from m. Vastus Lateralis analyzed by western blot
PTEN-induced putative kinase 1 (PINK1) mRNABefore and 2.5 hours after acute training session both at baseline and after 10 weeksBiopsies from m. Vastus Lateralis analyzed by western blot
TNF receptor associated factor 6 (TRAF6) mRNABefore and 2.5 hours after acute training session both at baseline and after 10 weeksBiopsies from m. Vastus Lateralis analyzed by western blot
transcription factor EB (Tfeb) mRNABefore and 2.5 hours after acute training session both at baseline and after 10 weeksBiopsies from m. Vastus Lateralis analyzed by western blot
Intramyocellular lipidsChange from baseline at 10 weeksOil-Red-O staining of muscle sections. Biopsy from m. Vastus Lateralis analyzed by immunohistochemistry
Muscle fiber type distributionChange from baseline at 10 weeksBiopsy from m. Vastus Lateralis analyzed by immunohistochemistry
Muscle fiber cross-sectional areaChange from baseline at 10 weeksBiopsy from m. Vastus Lateralis analyzed by immunohistochemistry
Muscle satellite cellsChange from baseline at 10 weeksBiopsy from m. Vastus Lateralis analyzed by immunohistochemistry
MyonucleiChange from baseline at 10 weeksBiopsy from m. Vastus Lateralis analyzed by immunohistochemistry
Myonuclei numberChange from baseline at 10 weeksBiopsy from m. Vastus Lateralis analyzed by confocal microscopy
Myonuclei locationChange from baseline at 10 weeksBiopsy from m. Vastus Lateralis analyzed by confocal microscopy
Amount of mitochondriaChange from baseline at 10 weeksBiopsy from m. Vastus Lateralis analyzed by confocal microscopy
Location of mitochondriaChange from baseline at 10 weeksBiopsy from m. Vastus Lateralis analyzed by confocal microscopy

Countries

Norway

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026